Biocon Biologics (BBL), a subsidiary of Biocon, today announced the successful completion of the transition of the acquired biosimilars business in ~120 countries across Advanced and Emerging Markets, a year ahead of schedule.

Over 10 Emerging Markets along with Japan, Australia and New Zealand have transitioned in this final phase of the integration of the biosimilars business acquired from Viatris. With the completion of this significant milestone, Biocon Biologics is now a unique, fully integrated ‘lab to market' biosimilars company committed to serving millions of patients across the globe.

Earlier in 2023, over 70 Emerging Markets were integrated in July, the North America business transitioned in September and the European business in November.